Gen-Probe outside Roche, Chugai merger
This article was originally published in Clinica
Executive Summary
Chugai Pharmaceutical's US diagnostics and blood screening unit, Gen-Probe, is to be spun off following the Tokyo company's acquisition by Switzerland's Roche Holding. The purchase of a majority holding in Chugai, announced last week, is expected to be completed by the last quarter of 2002 year, says Roche, whereafter Nippon Roche and Chugai will merge. The spin-off of San Diego-based Gen-Probe will take place prior to completion of the merger. Chugai will keep its name, but be known as a "member company of Roche".
You may also be interested in...
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.